Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
11.26
+0.26 (2.36%)
At close: May 1, 2026, 4:00 PM EDT
11.24
-0.02 (-0.18%)
After-hours: May 1, 2026, 7:12 PM EDT
Telix Pharmaceuticals Employees
As of December 31, 2025, Telix Pharmaceuticals had 1,184 total employees, including 1,120 full-time and 64 part-time employees. The number of employees increased by 950 or 405.98% compared to the previous year.
Employees
1,184
Change
950
Growth
405.98%
Revenue / Employee
$678,880
Profits / Employee
-$6,018
Market Cap
3.81B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1,184 | - | - | 1,120 | 64 |
| Mar 31, 2024 | 431 | 197 | 84.19% | 415 | 16 |
| Dec 31, 2022 | 234 | 76 | 48.10% | 234 | 0 |
| Dec 31, 2021 | 158 | - | - | 158 | 0 |
| Dec 31, 2017 | 9 | - | - | 9 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| ACADIA Pharmaceuticals | 798 |
| Arcus Biosciences | 601 |
| Crinetics Pharmaceuticals | 594 |
| Travere Therapeutics | 497 |
| Catalyst Pharmaceuticals | 182 |
| Edgewise Therapeutics | 146 |
| NewAmsterdam Pharma Company | 100 |
TLX News
- 1 day ago - Telix Presents Phase 2 OPTIMAL-PSMA Dosimetry Data For TLX597-Tx In Prostate Cancer Treatment - Nasdaq
- 1 day ago - TLX101-Px (Pixlumi®) MAA Accepted in Europe - GlobeNewsWire
- 2 days ago - Telix Pharmaceuticals Transcript: Status update - Transcripts
- 2 days ago - OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer - GlobeNewsWire
- 4 days ago - Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach - GlobeNewsWire
- 10 days ago - ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026 - GlobeNewsWire
- 17 days ago - Telix Pharma Doses First Patient In Phase 3 IPAX BrIGHT Trial Of TLX101-Tx; Prices $600 Mln Bonds - Nasdaq
- 17 days ago - Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma - GlobeNewsWire